One of the notable advancements in HIV treatment in recent decades is the significant reduction in side effects and improved efficacy of the antiretroviral drugs used today compared to older ones.
In 2019, South Africa began incorporating a new antiretroviral medication called dolutegravir into its treatment regimen, following a recommendation from the World Health Organization (WHO). Dolutegravir garnered much enthusiasm due to its minimal side effects, high effectiveness in suppressing HIV, and low likelihood of the virus developing resistance to it.
Within just four years, over 4.7 million individuals in South Africa transitioned to dolutegravir-based treatment, typically combined into a single pill with the antiretrovirals tenofovir and emtracitabine. The transition has been widely regarded as a success, supported by a significant study published in the Lancet medical journal, which indicated that individuals who switched to dolutegravir-based regimens were more likely to adhere to treatment and achieve viral suppression.
However, despite the overall positive outlook on dolutegravir-based HIV treatment, concerns regarding drug resistance have emerged. Recent reports, including a WHO publication on HIV drug resistance and various studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI), suggest that resistance to dolutegravir is emerging in specific populations, with levels of resistance higher than anticipated.
The WHO report highlighted resistance levels ranging from 3.9% to 8.6% across different surveys, with a peak of 19.6% among individuals with high viral loads who transitioned from other antiretroviral treatments to dolutegravir-based regimens.
Experts caution against alarm, emphasizing that while resistance cases have been identified, they primarily occur in specific contexts, such as individuals who failed previous treatments or were exposed to other integrase inhibitors. Moreover, the overall rates of resistance remain low when considering the broader population receiving dolutegravir.
Several studies presented at CROI examined resistance in specific populations, including those with high viral loads. While some studies reported higher-than-anticipated resistance rates, particularly among individuals with previous treatment failures, the overall incidence of resistance remains relatively low.
Experts stress the importance of continued surveillance for dolutegravir resistance to inform treatment strategies effectively. While there may be a need for adjustments in the future, proactive monitoring and research efforts are essential to address emerging challenges while maintaining effective HIV treatment programs.
In 2019, South Africa began incorporating a new antiretroviral medication called dolutegravir into its treatment regimen, following a recommendation from the World Health Organization (WHO). Dolutegravir garnered much enthusiasm due to its minimal side effects, high effectiveness in suppressing HIV, and low likelihood of the virus developing resistance to it.
Within just four years, over 4.7 million individuals in South Africa transitioned to dolutegravir-based treatment, typically combined into a single pill with the antiretrovirals tenofovir and emtracitabine. The transition has been widely regarded as a success, supported by a significant study published in the Lancet medical journal, which indicated that individuals who switched to dolutegravir-based regimens were more likely to adhere to treatment and achieve viral suppression.
However, despite the overall positive outlook on dolutegravir-based HIV treatment, concerns regarding drug resistance have emerged. Recent reports, including a WHO publication on HIV drug resistance and various studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI), suggest that resistance to dolutegravir is emerging in specific populations, with levels of resistance higher than anticipated.
The WHO report highlighted resistance levels ranging from 3.9% to 8.6% across different surveys, with a peak of 19.6% among individuals with high viral loads who transitioned from other antiretroviral treatments to dolutegravir-based regimens.
Experts caution against alarm, emphasizing that while resistance cases have been identified, they primarily occur in specific contexts, such as individuals who failed previous treatments or were exposed to other integrase inhibitors. Moreover, the overall rates of resistance remain low when considering the broader population receiving dolutegravir.
Several studies presented at CROI examined resistance in specific populations, including those with high viral loads. While some studies reported higher-than-anticipated resistance rates, particularly among individuals with previous treatment failures, the overall incidence of resistance remains relatively low.
Experts stress the importance of continued surveillance for dolutegravir resistance to inform treatment strategies effectively. While there may be a need for adjustments in the future, proactive monitoring and research efforts are essential to address emerging challenges while maintaining effective HIV treatment programs.
About this article
From the Medical Directory library. For advice about your own health, speak to your healthcare professional.
JOIN THE CONVERSATION
No comments yet. Add a thoughtful question or comment about this article.